Muscle-Specific Regulatory Elements for Sustained Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing gene delivery methods for muscle-directed gene therapy face challenges such as insufficient and transient transgene expression levels, inappropriate expression in unwanted cell types, and immune responses, particularly with adenoviral and lentiviral vectors, while conventional approaches lack consideration for evolutionary conserved regulatory motifs.
Innovation Solution
Utilizing a modified DDM-MDS strategy to identify evolutionarily conserved transcription factor binding site (TFBS) motifs for nucleic acid regulatory elements that enhance muscle-specific gene expression, integrated into expression cassettes and vectors like AAV, plasmids, and transposons, to achieve efficient and tissue-specific gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If adenoviral vectors are used for gene delivery to muscle, then transduction efficiency and cloning capacity are improved, but immune response and inflammatory reactions worsen
Solution Approach 1:
The patent extracts and removes the immunogenic viral components (adenoviral capsid proteins, viral promoters, and other viral elements) from the delivery system while retaining the essential gene delivery function. This is achieved by using non-viral plasmid DNA combined with synthetic muscle-specific regulatory elements, thereby eliminating the trigger for immune response while maintaining transduction efficiency.
Solution Approach 2:
The patent introduces muscle-specific regulatory elements (enhancers and promoters) as intermediaries between the plasmid DNA and muscle tissue. These regulatory elements act as mediators that facilitate specific binding to muscle cell nuclei and enhance transgene expression without triggering immune responses, thereby resolving the contradiction between delivery efficiency and immune safety.
2Productivity
If conventional trial-and-error vector design is used, then expression levels may be improved, but tissue specificity and loss of tissue specificity worsen
Solution Approach 1:
The patent applies preliminary action by pre-identifying and characterizing muscle-specific regulatory elements through bioinformatics analysis of evolutionary conserved sequences before constructing the expression vector. This preliminary characterization ensures that the regulatory elements have both high expression capability and inherent tissue specificity, eliminating the need for trial-and-error approaches that compromise tissue specificity.
Solution Approach 2:
The patent changes the parameters of the regulatory elements by optimizing the combination and arrangement of specific enhancer and promoter sequences to achieve both high expression levels and muscle-specificity. This systematic parameter optimization replaces the conventional trial-and-error method, ensuring precise tissue specificity is maintained while maximizing expression.
3Device complexity
If evolutionary conserved regulatory motifs are not included, then vector design complexity is reduced, but expression robustness and clinical translation worsen
Solution Approach 1:
The patent applies universality by using evolutionary conserved regulatory motifs that have been naturally selected across species for their robust function. These motifs serve multiple purposes: they provide muscle-specificity, ensure high expression levels, and guarantee reliability across different experimental and clinical conditions. This multi-functionality reduces the need for complex vector designs while maintaining robust expression.
4Quantity of substance
If plasmids are used for gene delivery, then cloning capacity and immunogenicity are improved, but transfection efficiency worsens
Solution Approach 1:
The patent applies local quality by enhancing specific regions of the plasmid with muscle-specific regulatory elements. The plasmid backbone maintains its simple structure and large cloning capacity, while localized insertion of potent muscle-specific enhancers and promoters at strategic positions dramatically improves transfection efficiency in muscle tissue without compromising the plasmid's fundamental advantages.
Data Source
AI summary
The present invention relates to nucleic acid regulatory elements that are able to enhance muscle-specific expression of genes, in particular expression in cardiac muscle and/or skeletal muscle, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. The present invention is particularly useful for applications using gene therapy, more particularly muscle-directed gene therapy, and for vaccination purposes.